150 µg Corifollitropin Alfa + 200 IU RecFSH/Follitropin beta (Days 1 to 7) + Placebo for Corifollitropin Alfa + Placebo for RecFSH/Follitropin beta + 200 IU RecFSH/Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + Progesterone
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
In Vitro Fertilization
Conditions
In Vitro Fertilization
Trial Timeline
Apr 19, 2006 → May 31, 2009
NCT ID
NCT00702273About 150 µg Corifollitropin Alfa + 200 IU RecFSH/Follitropin beta (Days 1 to 7) + Placebo for Corifollitropin Alfa + Placebo for RecFSH/Follitropin beta + 200 IU RecFSH/Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + Progesterone
150 µg Corifollitropin Alfa + 200 IU RecFSH/Follitropin beta (Days 1 to 7) + Placebo for Corifollitropin Alfa + Placebo for RecFSH/Follitropin beta + 200 IU RecFSH/Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + Progesterone is a pre-clinical stage product being developed by Organon for In Vitro Fertilization. The current trial status is completed. This product is registered under clinical trial identifier NCT00702273. Target conditions include In Vitro Fertilization.
What happened to similar drugs?
1 of 4 similar drugs in In Vitro Fertilization were approved
Approved (1) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
3
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00702273 | Pre-clinical | Completed |
Competing Products
8 competing products in In Vitro Fertilization